Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application
22 avr. 2021 08h00 HE
|
Revive Therapeutics Ltd.
TORONTO, April 22, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Reschedules Annual and Special Meeting and Provides Dial-In Information
15 avr. 2021 18h00 HE
|
Revive Therapeutics Ltd.
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Adjourns Annual and Special Meeting
12 avr. 2021 12h54 HE
|
Revive Therapeutics Ltd.
TORONTO, April 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
Revive Provides Dial-In Information for Annual and Special Meeting
08 avr. 2021 18h00 HE
|
Revive Therapeutics Ltd.
TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
24 mars 2021 08h28 HE
|
Revive Therapeutics Ltd.
TORONTO, March 24, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
19 mars 2021 07h30 HE
|
Revive Therapeutics Ltd.
TORONTO, March 19, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
26 févr. 2021 09h50 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
26 févr. 2021 08h33 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Acquires Unique Psilocybin Assets
17 févr. 2021 09h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
12 févr. 2021 09h42 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of...